文献速递眼底病与葡萄膜炎

脉络膜上腔曲安奈德治疗非感染性葡萄膜炎:真实世界临床结局影响

Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes.
PubMed 文献 · Am J Ophthalmol · 2024-12-05

回顾性介入病例系列纳入单机构61眼(51例)接受脉络膜上腔曲安奈德注射的非感染性葡萄膜炎患者,黄斑水肿眼平均中心子区厚度从注射时437.61微米降至6周后348.17微米(平均差89.44微米,p<0.0001,n=47),10眼荧光素眼底血管造影评分从11.74改善至9.14(平均差2.60,p=0.047),无严重不良事件。

要点

  • 黄斑水肿眼脉络膜上腔曲安奈德注射后6周平均中心子区厚度改善89.44微米(p<0.0001,n=47)。
  • 10眼注射时及6周后行荧光素眼底血管造影,平均评分从11.74改善至9.14(p=0.047)。
  • 6、12、24周随访时分别有17%(8/48眼)、48%(14/29眼)、41%(9/22眼)需追加黄斑水肿治疗。

核心结论

  • 脉络膜上腔曲安奈德在真实世界临床实践中使黄斑水肿眼中心子区厚度及荧光素眼底血管造影渗漏显著改善,且副作用情况良好。

研究设计与样本

  • 回顾性介入病例系列,纳入2022年1月1日至2024年7月1日期间单机构接受脉络膜上腔曲安奈德注射的61眼(51例)。

主要发现

  • 52眼因葡萄膜炎性黄斑水肿接受脉络膜上腔曲安奈德注射,平均中心子区厚度从注射时437.61微米降至6周后348.17微米(平均差89.44微米,p<0.0001,n=47)。
  • 6、12、24周随访时分别有17%(8/48眼)、48%(14/29眼)、41%(9/22眼)需追加黄斑水肿治疗。
  • 在所有访视点(6、12、24周)均随访的17眼中,41.2%(7/17眼)在24周随访期内无需任何追加治疗。
  • 10眼在注射时及6周后行荧光素眼底血管造影,平均评分从11.74改善至9.14(平均差2.60,p=0.047)。
  • 未发生严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate clinically relevant outcomes following suprachoroidal triamcinolone acetonide (TA) injection in eyes with noninfectious uveitis. DESIGN: Retrospective interventional case series. METHODS: Sixty-one eyes (51 patients) who underwent suprachoroidal TA injection between January 1, 2022 and July 1, 2024 were included from a single institution. Main outcome measures included change in central subfield thickness (CST) and best-corrected visual acuity (BCVA) at 6, 12, and 24 weeks in eyes with macular edema and improvement in fluorescein angiography (FA) score at 6 weeks in eyes who underwent FA. RESULTS: Fifty-two eyes underwent suprachoroidal TA injection for uveitic macular edema. Mean CST improved from 437.61 microns at time of injection to 348.17 microns 6 weeks after (mean difference 89.44 microns, p < 0.0001, n = 47). Additional treatment for macular edema was required for 17% (8/48 eyes), 48% (14/29 eyes), and 41% (9/22 eyes) of eyes that returned for follow-up at 6, 12, and 24 weeks, respectively. Of the 17 eyes that returned for follow-up at all visits (6, 12, and 24 weeks), 41.2% (7/17 eyes) did not require any additional treatment during the 24-week follow-up period. Ten eyes underwent FA at time of injection and 6 weeks later. The mean FA score improved from 11.74 to 9.14 (mean difference 2.60, p = 0.047). No serious adverse events occurred. CONCLUSIONS: Suprachoroidal TA resulted in significant improvement in outcome measures, including central subfield thickness in eyes with macular edema, and leakage on fluorescein angiography, with a favorable side effect profile in real-world clinical practice.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Panse K, Hang A, Ruiz J, et al. Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes. Am J Ophthalmol. 2024. PMID: 39645179. doi:10.1016/j.ajo.2024.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。